Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients†

Abstract

During boceprevir monotherapy, resistance mutations at six positions within the NS3 protease were detected by way of clonal sequence analysis. All mutations are associated with reduced replicative fitness estimated by mathematical modeling and show cross-resistance to telaprevir.